Dhoot Dilsher S, Boucher Nick, Pitcher John D, Saroj Namrata
Ophthalmic Surg Lasers Imaging Retina. 2021 Jun;52(6):312-318. doi: 10.3928/23258160-20210528-03. Epub 2021 Jun 1.
To evaluate rates of suspected endophthalmitis following intravitreal injections of aflibercept, bevacizumab, ranibizumab (vial and pre-filled), dexamethasone implant, and triamcinolone in clinical practice.
Retrospective study of aggregated electronic medical records from the Vestrum Health Database. Eyes with a diagnosis of suspected endophthalmitis based on billing codes between January 2013 and June 2019 were included.
Total number of injections, suspected endophthalmitis cases, and medication rate, respectively, were: aflibercept (1,412,699; 687; 0.049%); bevacizumab (1,467,722; 379; 0.026%); ranibizumab vial (884,061; 233; 0.026%), ranibizumab pre-filled (427,763; 96; 0.022%); dexamethasone implant (49,464; 53; 0.107%); and triamcinolone (75,038; 110; 0.147%). Rates were lower for bevacizumab and ranibizumab (vial and pre-filled) compared to aflibercept, dexamethasone implant, and triamcinolone ( < .05). Triamcinolone had a higher rate compared to all of the other medications ( < .05).
Suspected endophthalmitis rates following anti-vascular endothelial growth factor injections in clinical practice were similar to reported rates in clinical trials. Rates of suspected endophthalmitis following steroid injections trended higher with significantly higher rates with triamcinolone. .
评估在临床实践中玻璃体内注射阿柏西普、贝伐单抗、雷珠单抗（瓶装和预充式）、地塞米松植入剂和曲安奈德后疑似眼内炎的发生率。
对Vestrum健康数据库中的汇总电子病历进行回顾性研究。纳入2013年1月至2019年6月期间根据计费代码诊断为疑似眼内炎的眼睛。
注射总数、疑似眼内炎病例数及发生率分别为：阿柏西普（1,412,699；687；0.049%）；贝伐单抗（1,467,722；379；0.026%）；瓶装雷珠单抗（884,061；233；0.026%），预充式雷珠单抗（427,763；96；0.022%）；地塞米松植入剂（49,464；53；0.107%）；曲安奈德（75,038；110；0.147%）。与阿柏西普、地塞米松植入剂和曲安奈德相比，贝伐单抗和雷珠单抗（瓶装和预充式）的发生率较低（P<0.05）。曲安奈德的发生率高于所有其他药物（P<0.05）。
临床实践中抗血管内皮生长因子注射后疑似眼内炎的发生率与临床试验报告的发生率相似。类固醇注射后疑似眼内炎的发生率呈上升趋势，曲安奈德的发生率显著更高。
